The FDA has approved a new drug called revumenib that can be taken orally to treat acute leukemia in patients 1 year or older. The drug will be marketed under the brand name Revuforj.

precise and personalized treatments for conditions, such as rheumatoid arthritis, type 1 diabetes and autoimmune neurologic ...

Most patients with rheumatoid arthritis or spondyloarthritis had significant antibody responses to COVID vaccine boosters, whether or not their immunomodulatory medications were held.

SetPoint Medical, a clinical-stage healthcare company dedicated to people living with chronic autoimmune diseases, today ...

The first poster demonstrates proof-of-concept data that Aqtual's therapy selection test can predict treatment response in patients with RA. The second poster provides an interim analysis from ...

Substantial improvements in ultrasound technology and expanded use of it have necessitated an update of the 2012 ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today ...

The test will measure levels of the 14-3-3eta protein, which is used in the diagnosis and management of inflammatory diseases including rheumatoid arthritis.

Use of an implantable vagus nerve stimulation device was safe and effective for treating RA among patients who previously failed treatment with at least 1 b/tsDMARD.

The use of biologic and targeted therapies for children with juvenile idiopathic arthritis (JIA) surpassed more typical therapies in recent years, according to researchers.